Entering text into the input field will update the search result below

ETF Deathwatch For March 2020

Invest With An Edge profile picture
Invest With An Edge
652 Followers

Summary

  • The ETF Deathwatch decreased in size in March. Sixteen exchange-traded products ("ETPs") were added to the list, and 54 funds were removed.
  • Thirty-three of those funds were removed due to increased health and 21 were due to asset managers closing their funds.
  • The low number of additions to the Deathwatch in March comes as a surprise, considering how turbulent the month was for U.S. indexes.

By Ansh Chaudhary

The ETF Deathwatch decreased in size in March. Sixteen exchange-traded products ("ETPs") were added to the list, and 54 funds were removed. Thirty-three of those funds were removed due to increased health and 21 were due to asset managers closing their funds. The low number of additions to the Deathwatch in March comes as a surprise, considering how turbulent the month was for U.S. indexes.

The funds added to the list in March were a mix of niche and municipal bond products. All of the additions were due to low average daily volume. These additions have enough assets under management ("AUM") to keep them from closure; however, our system takes into account both AUM and volume, so it's likely that should volume and interest remain low, these funds may be considered for closure.

The low volume in these funds could be due to the nature of their investment product. Many of the funds added to the Deathwatch list are niche funds. Because equity markets fell sharply in March on news of the effects of COVID-19 on businesses and economies worldwide, it makes sense that some leveraged big-bank, non-U.S. small-cap, ESG large-cap, and emerging-market funds might find themselves on the list. Investors tend to avoid niche products in these areas of investing during market downturns, as they are likely to be hit much harder than other passive, index-tracking, non-niche products.

However, most of the removals from the Deathwatch due to improved health are also niche products. But after taking a closer look, we find that quite a few of these are factor ETFs-value, dividend, and so on. It makes sense that interest may increase in some of these funds during a market downturn, as they provide active downside protection when they shift to highly ranked companies while most of the market is going down. Some biopharmaceutical

This article was written by

Invest With An Edge profile picture
652 Followers
Invest With An Edge (http://investwithanedge.com) is a free trading resource for everyday investors. Published by All Star Investor (http://www.allstarinvestor.com/), we’ve been delivering solid investing advice since 1991. We specialize in Exchange Traded Funds (ETFs), Mutual Funds, and Stock investing. This website includes: --Daily Market Commentary (http://investwithanedge.com/commentary) We cover the markets from a unique perspective. Our daily insight will help you to think about investing in a not-so-common way and will help you gain an edge in the markets. --Leadership Strategy Trading Method (http://investwithanedge.com/leadership-strategy) This growth strategy takes all investing styles (Large Cap Growth, Small Cap Value, etc.) and helps you to invest in the ones displaying true market leadership. --Weekly Investing Newsletter (http://investwithanedge.com/invest-with-an-edge-newsletter) We provide a powerful mid-week review of the markets with a focus on sectors, styles, and international positions. We also include a timely Pick of the Week for investors looking for more ideas.

Recommended For You

Comments

Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.